AI News Sentiment & Analysis
Corcept Therapeutics Incorporated (CORT) — AI News Sentiment & Analysis
7 recent AI analyses of Corcept Therapeutics Incorporated (CORT) stock news and press releases, with sentiment and confidence scoring updated continuously.
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
BullishRegulatory DecisionFDA resubmission of NDA for relacorilant, triggering a new six-month review period. (Timing: Within 6 months)Jun 17, 2026Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
BullishClinical ResultsPresentation of new clinical data at the American Diabetes Association's Scientific Sessions showing improved outcomes for Korlym in Type 2 Diabetes patients treated with GLP-1s. This significantly expands the potential market for Korlym. (Timing: Immediate)Jun 6, 2026Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
BullishClinical ResultsThe presentation of new, compelling overall survival data from the pivotal Phase 3 ROSELLA trial for Lifyorli at ASCO 2026 will drive increased adoption and market penetration for the recently FDA-approved drug. (Timing: Immediate impact from presentation, with sustained adoption over the next 12-24 months as physicians incorporate the new data into practice.)May 29, 2026Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
BullishClinical ResultsPositive two-year overall survival data from the Phase 2 DAZALS study of dazucorilant in Amyotrophic Lateral Sclerosis (ALS), showing an 87% reduction in risk of death. (Timing: Initiation of pivotal Phase 3 study later this year; future regulatory approvals will depend on Phase 3 outcomes.)Apr 30, 2026Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
BearishThe formal filing of a securities class action lawsuit against Corcept Therapeutics, alleging the company misled investors about critical FDA warnings for its drug relacorilant. (Timing: The lawsuit's legal proceedings are ongoing, with a lead plaintiff deadline of April 21, 2026. This indicates a prolonged period of legal uncertainty, potentially extending over several months to years.)Mar 12, 2026Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
BearishThe official filing of a securities class action lawsuit, potentially leading to further negative developments or financial penalties for the company. (Timing: Ongoing legal proceedings (likely several months to years))Feb 26, 2026Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
BullishThe primary catalysts are the strong 2026 revenue guidance ($900M - $1,000M), the PDUFA date of July 11, 2026, for relacorilant in platinum-resistant ovarian cancer, and positive overall survival results from the ROSELLA study for the same indication. Several other clinical trial readouts are expected by the end of 2026 and into 2027. (Timing: Medium-term (July 2026 for PDUFA, ongoing into 2027 for other clinical trial readouts and full realization of 2026 guidance).)Feb 24, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Corcept Therapeutics Incorporated (CORT) bullish or bearish right now?
AI Sentiment on CORT: 5 Bullish, 2 Bearish.
What was the latest AI analysis for Corcept Therapeutics Incorporated (CORT)?
The latest analysis was published on 6/17/2026 with the headline: "Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome".
How does Bekodia analyze Corcept Therapeutics Incorporated (CORT) stock?
Bekodia uses advanced AI models to process Corcept Therapeutics Incorporated (CORT) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.